search
Back to results

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

Primary Purpose

Non-Small Cell Lung Cancer

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Atezolizumab
Tiragolumab
Matching Placebo
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Small Cell Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
  • No prior systemic treatment for metastatic NSCLC
  • High tumor tissue PD-L1 expression
  • Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Adequate hematologic and end-organ function
  • For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.

Exclusion Criteria:

  • Known mutation in the EGFR gene or an ALK fusion oncogene
  • Symptomatic, untreated, or actively progressing central nervous system metastases
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Positive test result for human immunodeficiency virus (HIV)
  • Active hepatitis B or hepatitis C
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.

Sites / Locations

  • Rocky Mountain Cancer Center - Denver
  • Yale Cancer Center
  • SCRI Florida Cancer Specialists North; Research Office North Region.
  • SCRI Florida Cancer Specialists PAN
  • Illinois Cancer Specialists
  • Karmanos Cancer Institute..
  • US oncology research at Minnesota Oncology
  • Onc/Hem Care Clin Trials LLC
  • Sarah Cannon Research Institute
  • Texas Onc-Central Austin CA Ct
  • Virginia Cancer Specialists (Fairfax) - USOR
  • Onc & Hem Assoc SW Virginia
  • Northwest Cancer Specialists - Vancouver
  • Fundación CENIT para la Investigación en Neurociencias
  • Fundación Respirar
  • CEMER Centro Medico de Enfermedades Respiratorias
  • Clínica Viedma
  • St Vincent's Hospital Sydney
  • Princess Alexandra Hospital
  • Frankston Hospital; Oncology/Haematology
  • Austin Hospital Olivia Newton John Cancer Centre
  • Peter Maccallum Cancer Centre
  • Ordensklinikum Linz Elisabethinen
  • Klinikum Wels-Grieskirchen; Lungenabt.
  • Klinik Penzing; Abteilung für Atemwegs- und Lungenkrankheiten
  • Krankenhaus Nord - Klinik Floridsdorf; Abteilung Pulmologie
  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
  • Hospital Sao Lucas - PUCRS
  • Hospital de Cancer de Barretos
  • Beijing Cancer HospitalRecruiting
  • Beijing Chest Hospital; Oncology DepartmentRecruiting
  • The First Hospital of Jilin University
  • Changzhou First People's HospitalRecruiting
  • Sichuan Cancer HospitalRecruiting
  • West China Hospital, Sichuan UniversityRecruiting
  • Chongqing Cancer HospitalRecruiting
  • Fujian Cancer HospitalRecruiting
  • Cancer Center of Guangzhou Medical UniversityRecruiting
  • Hainan General HospitalRecruiting
  • Sir Run Run Shaw Hospital Zhejiang UniversityRecruiting
  • Harbin Medical University Cancer HospitalRecruiting
  • Jinan Central HospitalRecruiting
  • Meizhou People's Hospital
  • The Second Affiliated Hospital to Nanchang UniversityRecruiting
  • The 1st Affiliated Hospital of Nanchang Unversity
  • Nantong Tumor HospitalRecruiting
  • Fudan University Shanghai Cancer CenterRecruiting
  • Zhongshan Hospital Fudan UniversityRecruiting
  • Shanghai Pulmonary HospitalRecruiting
  • Tianjin Cancer HospitalRecruiting
  • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
  • First Affiliated Hospital of Medical College of Xi'an Jiaotong UniversityRecruiting
  • The First Affiliated Hospital of Xiamen UniversityRecruiting
  • Zhejiang Cancer HospitalRecruiting
  • Henan Cancer Hospital
  • Aalborg Universitetshospital
  • Rigshospitalet; Onkologisk Klinik
  • Sjællands Universitetshospital, Roskilde; Klinisk Onkologisk Afdeling og Palliativ Enhed
  • Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
  • Centre Hospitalier Intercommunal; Service de Pneumologie
  • Centre Georges Francois Leclerc; Recherche Clinique
  • CHRU Nantes
  • CH de Saint Quentin
  • Centre Paul Strauss; Oncologie Medicale
  • CHU de Toulouse - Hôpital Larrey
  • Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
  • LungenClinic Großhansdorf GmbH
  • Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin I
  • Fachklinik für Lungenerkrankungen
  • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein; Onk & Pal
  • Gemeinschaftspraxis für Hämatologie und Onkologie
  • Klinik Schillerhöhe; Pneumologische Onkologie
  • Sotiria Hospital
  • Metropolitan Hospital
  • Univ General Hosp Heraklion; Medical Oncology
  • University Hospital of Larissa;Department of Medical Oncology
  • Diavalkaniko Hospital
  • Orszagos Koranyi TBC es Pulmonologiai Intezet
  • Veszprem Megyei Onkormanyzat Tudogyogyintezete; Tudogyogyaszati Ambulancia
  • Matrai Gyogyintezet
  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
  • Azienda Ospedaliera San Giuseppe Moscati
  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
  • A.O. Universitaria Di Parma; Oncologia Medica
  • Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica
  • Azienda Ospedaliera San Camillo Forlanini
  • Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia
  • Asst Di Monza
  • Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
  • Azienda Sanitaria Ospedaliera S Luigi Gonzaga; SSD Oncologia Polomonare (II PAD. IV PIANO)
  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
  • IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
  • Aichi Cancer Center
  • National Cancer Center Hospital East
  • Kyushu University Hospital
  • Sendai Kousei Hospital
  • Niigata Cancer Center Hospital
  • Okayama University Hospital
  • Osaka International Cancer Institute
  • Kindai University Hospital
  • Saitama Cancer Center
  • National Hospital Organization Kinki-Chuo Chest Medical Center
  • Shizuoka Cancer Center
  • National Cancer Center Hospital
  • The Cancer Institute Hospital of JFCR
  • Chungbuk National University Hospital
  • National Cancer Center
  • Ajou University Medical Center
  • Gachon University Gil Medical Center
  • Chonnam National University Hwasun Hospital
  • Seoul National University Bundang Hospital
  • Seoul National University Hospital
  • Kangbuk Samsung Medical Center
  • Severance Hospital, Yonsei University Health System
  • Asan Medical Center
  • Samsung Medical Center
  • Korea University Guro Hospital
  • St. Vincent's Hospital
  • Health Pharma Professional Research
  • Cryptex Investigacion Clinica SA de CV
  • AVIX Investigación Clínica S.C
  • Cuidados oncologicos
  • Jeroen Bosch Ziekenhuis
  • Hagaziekenhuis, locatie Leyweg
  • Ziekenhuis Gelderse Vallei
  • Medisch Centrum Leeuwarden
  • Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica
  • Instituto Nacional de Enfermedades Neoplasicas
  • Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional
  • Clinica Ricardo Palma
  • Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
  • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie; Oddzial onkologii z pododdzialem chemioterapii
  • Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
  • Main Military Clinical Hospital named after N.N. Burdenko
  • MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy
  • Institute of Oncology
  • Leningrad Regional Clinical Hospital
  • St. Petersburg Med Univ; n.a. I.P. Pavlov; Pulmonology Research
  • St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
  • City Clinical Hospital #1
  • Regional Clinical Oncology Hospital
  • Clinical Center of Serbia
  • University Hospital Medical Center Bezanijska kosa
  • Institute for pulmonary diseases of Vojvodina
  • Hospital Universitario Germans Trias i Pujol
  • Hospital Universitario Puerta de Hierro - Majadahonda
  • Hospital General Universitario de Alicante
  • Hospital Universitari Vall d'Hebron
  • Hospital 12 de Octubre; Servicio de Digestivo
  • Hospital Regional Universitario de Malaga
  • Hospital Universitario Virgen del Rocío
  • Hosp Clinico Univ Lozano Blesa; División De Oncología Médica
  • Universitaetsspital Basel; Onkologie
  • Inselspital Bern; Universitätsklinik für medizinische Onkologie
  • CHUV; Departement d'Oncologie
  • Kantonsspital St.Gallen Medizin Onkologie; Klinik fuer Onkologie und Haematologie
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
  • Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine
  • Taipei Medical University ?Shuang Ho Hospital
  • Taichung Veterans General Hospital; Dept of Internal Medicine
  • National Cheng Kung Uni Hospital; Dept of Hematology and Oncology
  • Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology
  • Chang Gung Memorial Hospital - Linkou Branch
  • National Taiwan University Hospital; Oncology
  • Chulalongkorn Hospital; Medical Oncology
  • Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
  • Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
  • Songklanagarind Hospital; Department of Internal Medicine, Division of Respiratory
  • Adana Baskent University Hospital; Medical Oncology
  • Hacettepe University Medical Faculty
  • Istanbul University Cerrahpasa Faculty of MedicineRecruiting
  • Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
  • Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
  • Inonu University Medical Faculty of Medicine; Medical Oncology Department
  • City Clinical Hospital #4
  • Ivano-Frankivsk Regional Oncology Center
  • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council; Chemotherapy Department
  • Sumy Regional Clinical Onc Ctr
  • Uzhgorod Nat. University Central Municip Hosp; Onc Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Tiragolumab + Atezolizumab

Placebo + Atezolizumab

Arm Description

Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Outcomes

Primary Outcome Measures

Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set
Overall Survival (OS) in the Primary Analysis Set
Percentage of Participants With Adverse Events (AEs)
Percentage of Participants With Cytokine-Release Syndrome (CRS)

Secondary Outcome Measures

Investigator-Assessed PFS in the Secondary Analysis Set
OS in the Secondary Analysis Set
Investigator-Assessed Confirmed Objective Response Rate (ORR)
Investigator-Assessed Duration of Response (DOR)
Investigator-Assessed PFS Rates at 6 Months and 12 Months
OS Rates at 12 Months and 24 Months
Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score
TTCD using EORTC QLQ-C30 is an initial 10-point decrease in global health status (GHS)/quality of life (QoL) and functioning from baseline that must be held for at least two consecutive assessments or an initial clinically meaningful decrease above baseline followed by death. EORTC QLQ-C30: a self-reported measure, consisting of 30 questions that assess 5 aspects of participants functioning (physical, emotional, role, cognitive and social), 3 symptom scales (fatigue, nausea and vomiting and pain), GHS and QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) with a recall period of the previous week. Functioning items are scored on a 4-point scale: 1=Not at all to 4=Very much, with higher score indicating worse outcome. Symptom items (GHS and QoL) are scored on a 7-point scale: 1=Very poor to 7=Excellent. Scores will be linearly transformed with a minimum score of 0 and maximum score of 100. Higher score indicates better outcome.

Full Information

First Posted
March 2, 2020
Last Updated
October 5, 2023
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT04294810
Brief Title
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
Acronym
SKYSCRAPER-01
Official Title
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 4, 2020 (Actual)
Primary Completion Date
February 21, 2025 (Anticipated)
Study Completion Date
February 21, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Small Cell Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
660 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tiragolumab + Atezolizumab
Arm Type
Experimental
Arm Description
Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Arm Title
Placebo + Atezolizumab
Arm Type
Placebo Comparator
Arm Description
Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
Atezolizumab
Other Intervention Name(s)
Tecentriq
Intervention Description
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Intervention Type
Drug
Intervention Name(s)
Tiragolumab
Other Intervention Name(s)
MTIG7192A
Intervention Description
Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Intervention Type
Drug
Intervention Name(s)
Matching Placebo
Intervention Description
Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Primary Outcome Measure Information:
Title
Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set
Time Frame
From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months)
Title
Overall Survival (OS) in the Primary Analysis Set
Time Frame
From randomization to death from any cause (up to approximately 59 months)
Title
Percentage of Participants With Adverse Events (AEs)
Time Frame
Up to approximately 59 months
Title
Percentage of Participants With Cytokine-Release Syndrome (CRS)
Time Frame
Up to approximately 59 months
Secondary Outcome Measure Information:
Title
Investigator-Assessed PFS in the Secondary Analysis Set
Time Frame
From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months)
Title
OS in the Secondary Analysis Set
Time Frame
From randomization to death from any cause (up to approximately 59 months)
Title
Investigator-Assessed Confirmed Objective Response Rate (ORR)
Time Frame
From randomization up to approximately 59 months
Title
Investigator-Assessed Duration of Response (DOR)
Time Frame
From the first occurrence of a documented confirmed objective response to disease progression or death from any cause, whichever occurs first (up to approximately 59 months)
Title
Investigator-Assessed PFS Rates at 6 Months and 12 Months
Time Frame
6 months, 12 months
Title
OS Rates at 12 Months and 24 Months
Time Frame
12 months, 24 months
Title
Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score
Description
TTCD using EORTC QLQ-C30 is an initial 10-point decrease in global health status (GHS)/quality of life (QoL) and functioning from baseline that must be held for at least two consecutive assessments or an initial clinically meaningful decrease above baseline followed by death. EORTC QLQ-C30: a self-reported measure, consisting of 30 questions that assess 5 aspects of participants functioning (physical, emotional, role, cognitive and social), 3 symptom scales (fatigue, nausea and vomiting and pain), GHS and QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) with a recall period of the previous week. Functioning items are scored on a 4-point scale: 1=Not at all to 4=Very much, with higher score indicating worse outcome. Symptom items (GHS and QoL) are scored on a 7-point scale: 1=Very poor to 7=Excellent. Scores will be linearly transformed with a minimum score of 0 and maximum score of 100. Higher score indicates better outcome.
Time Frame
From randomization until the first confirmed clinically meaningful deterioration (up to approximately 59 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC No prior systemic treatment for metastatic NSCLC High tumor tissue PD-L1 expression Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) Adequate hematologic and end-organ function For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry. Exclusion Criteria: Known mutation in the EGFR gene or an ALK fusion oncogene Symptomatic, untreated, or actively progressing central nervous system metastases Active or history of autoimmune disease or immune deficiency History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome Severe infection within 4 weeks prior to initiation of study treatment Positive test result for human immunodeficiency virus (HIV) Active hepatitis B or hepatitis C Treatment with investigational therapy within 28 days prior to initiation of study treatment Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reference Study ID Number: GO41717 https://forpatients.roche.com/
Phone
888-662-6728 (U.S. Only)
Email
global-roche-genentech-trials@gene.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trial
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
Rocky Mountain Cancer Center - Denver
City
Littleton
State/Province
Colorado
ZIP/Postal Code
80120
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Yale Cancer Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
SCRI Florida Cancer Specialists North; Research Office North Region.
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
SCRI Florida Cancer Specialists PAN
City
Tallahassee
State/Province
Florida
ZIP/Postal Code
32308
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Illinois Cancer Specialists
City
Arlington Heights
State/Province
Illinois
ZIP/Postal Code
60005
Country
United States
Individual Site Status
Withdrawn
Facility Name
Karmanos Cancer Institute..
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Individual Site Status
Withdrawn
Facility Name
US oncology research at Minnesota Oncology
City
Saint Paul
State/Province
Minnesota
ZIP/Postal Code
55102
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Onc/Hem Care Clin Trials LLC
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Individual Site Status
Withdrawn
Facility Name
Sarah Cannon Research Institute
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Completed
Facility Name
Texas Onc-Central Austin CA Ct
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Individual Site Status
Withdrawn
Facility Name
Virginia Cancer Specialists (Fairfax) - USOR
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Completed
Facility Name
Onc & Hem Assoc SW Virginia
City
Salem
State/Province
Virginia
ZIP/Postal Code
24153
Country
United States
Individual Site Status
Completed
Facility Name
Northwest Cancer Specialists - Vancouver
City
Vancouver
State/Province
Washington
ZIP/Postal Code
98684
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Fundación CENIT para la Investigación en Neurociencias
City
Buenos Aires
ZIP/Postal Code
C1125ABD
Country
Argentina
Individual Site Status
Withdrawn
Facility Name
Fundación Respirar
City
Capital Federal
ZIP/Postal Code
1426
Country
Argentina
Individual Site Status
Withdrawn
Facility Name
CEMER Centro Medico de Enfermedades Respiratorias
City
Vicente López
ZIP/Postal Code
B1602DQD
Country
Argentina
Individual Site Status
Withdrawn
Facility Name
Clínica Viedma
City
Viedma Rio Negro
ZIP/Postal Code
R8500ACE
Country
Argentina
Individual Site Status
Withdrawn
Facility Name
St Vincent's Hospital Sydney
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Individual Site Status
Withdrawn
Facility Name
Princess Alexandra Hospital
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Individual Site Status
Active, not recruiting
Facility Name
Frankston Hospital; Oncology/Haematology
City
Frankston
State/Province
Victoria
ZIP/Postal Code
3199
Country
Australia
Individual Site Status
Withdrawn
Facility Name
Austin Hospital Olivia Newton John Cancer Centre
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Individual Site Status
Completed
Facility Name
Peter Maccallum Cancer Centre
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3000
Country
Australia
Individual Site Status
Completed
Facility Name
Ordensklinikum Linz Elisabethinen
City
Linz
ZIP/Postal Code
4020
Country
Austria
Individual Site Status
Completed
Facility Name
Klinikum Wels-Grieskirchen; Lungenabt.
City
Wels
ZIP/Postal Code
4600
Country
Austria
Individual Site Status
Withdrawn
Facility Name
Klinik Penzing; Abteilung für Atemwegs- und Lungenkrankheiten
City
Wien
ZIP/Postal Code
1140
Country
Austria
Individual Site Status
Active, not recruiting
Facility Name
Krankenhaus Nord - Klinik Floridsdorf; Abteilung Pulmologie
City
Wien
ZIP/Postal Code
1210
Country
Austria
Individual Site Status
Active, not recruiting
Facility Name
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
City
Ijui
State/Province
RS
ZIP/Postal Code
98700-000
Country
Brazil
Individual Site Status
Active, not recruiting
Facility Name
Hospital Sao Lucas - PUCRS
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90610-000
Country
Brazil
Individual Site Status
Withdrawn
Facility Name
Hospital de Cancer de Barretos
City
Barretos
State/Province
SP
ZIP/Postal Code
14784-400
Country
Brazil
Individual Site Status
Completed
Facility Name
Beijing Cancer Hospital
City
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Recruiting
Facility Name
Beijing Chest Hospital; Oncology Department
City
Beijing
ZIP/Postal Code
101149
Country
China
Individual Site Status
Recruiting
Facility Name
The First Hospital of Jilin University
City
Changchun City
ZIP/Postal Code
130021
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Changzhou First People's Hospital
City
Changzhou
ZIP/Postal Code
213003
Country
China
Individual Site Status
Recruiting
Facility Name
Sichuan Cancer Hospital
City
Chengdu City
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Name
West China Hospital, Sichuan University
City
Chengdu
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Name
Chongqing Cancer Hospital
City
Chongqing
ZIP/Postal Code
400030
Country
China
Individual Site Status
Recruiting
Facility Name
Fujian Cancer Hospital
City
Fuzhou
ZIP/Postal Code
350014
Country
China
Individual Site Status
Recruiting
Facility Name
Cancer Center of Guangzhou Medical University
City
Guangzhou
ZIP/Postal Code
510000
Country
China
Individual Site Status
Recruiting
Facility Name
Hainan General Hospital
City
Haikou
ZIP/Postal Code
570311
Country
China
Individual Site Status
Recruiting
Facility Name
Sir Run Run Shaw Hospital Zhejiang University
City
Hangzhou City
ZIP/Postal Code
310016
Country
China
Individual Site Status
Recruiting
Facility Name
Harbin Medical University Cancer Hospital
City
Harbin
ZIP/Postal Code
150081
Country
China
Individual Site Status
Recruiting
Facility Name
Jinan Central Hospital
City
Jinan City
ZIP/Postal Code
250013
Country
China
Individual Site Status
Recruiting
Facility Name
Meizhou People's Hospital
City
Meizhou City
ZIP/Postal Code
514031
Country
China
Individual Site Status
Active, not recruiting
Facility Name
The Second Affiliated Hospital to Nanchang University
City
Nanchang
ZIP/Postal Code
330006
Country
China
Individual Site Status
Recruiting
Facility Name
The 1st Affiliated Hospital of Nanchang Unversity
City
Nanchang
ZIP/Postal Code
330019
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Nantong Tumor Hospital
City
Nantong City
ZIP/Postal Code
226361
Country
China
Individual Site Status
Recruiting
Facility Name
Fudan University Shanghai Cancer Center
City
Shanghai City
ZIP/Postal Code
200120
Country
China
Individual Site Status
Recruiting
Facility Name
Zhongshan Hospital Fudan University
City
Shanghai
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Name
Shanghai Pulmonary Hospital
City
Shanghai
ZIP/Postal Code
200433
Country
China
Individual Site Status
Recruiting
Facility Name
Tianjin Cancer Hospital
City
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Recruiting
Facility Name
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
City
Wuhan City
ZIP/Postal Code
430022
Country
China
Individual Site Status
Active, not recruiting
Facility Name
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
City
Xi'an
ZIP/Postal Code
710061
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Xiamen University
City
Xiamen
ZIP/Postal Code
361003
Country
China
Individual Site Status
Recruiting
Facility Name
Zhejiang Cancer Hospital
City
Zhejiang
ZIP/Postal Code
310022
Country
China
Individual Site Status
Recruiting
Facility Name
Henan Cancer Hospital
City
Zhengzhou
ZIP/Postal Code
450008
Country
China
Individual Site Status
Withdrawn
Facility Name
Aalborg Universitetshospital
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Individual Site Status
Completed
Facility Name
Rigshospitalet; Onkologisk Klinik
City
København Ø
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Completed
Facility Name
Sjællands Universitetshospital, Roskilde; Klinisk Onkologisk Afdeling og Palliativ Enhed
City
Roskilde
ZIP/Postal Code
4000
Country
Denmark
Individual Site Status
Completed
Facility Name
Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Withdrawn
Facility Name
Centre Hospitalier Intercommunal; Service de Pneumologie
City
Creteil
ZIP/Postal Code
94010
Country
France
Individual Site Status
Withdrawn
Facility Name
Centre Georges Francois Leclerc; Recherche Clinique
City
Dijon
ZIP/Postal Code
21079
Country
France
Individual Site Status
Withdrawn
Facility Name
CHRU Nantes
City
Nantes
ZIP/Postal Code
44093
Country
France
Individual Site Status
Withdrawn
Facility Name
CH de Saint Quentin
City
Saint Quentin
ZIP/Postal Code
2100
Country
France
Individual Site Status
Withdrawn
Facility Name
Centre Paul Strauss; Oncologie Medicale
City
Strasbourg
ZIP/Postal Code
67065
Country
France
Individual Site Status
Withdrawn
Facility Name
CHU de Toulouse - Hôpital Larrey
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Withdrawn
Facility Name
Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
City
Frankfurt
ZIP/Postal Code
60488
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
LungenClinic Großhansdorf GmbH
City
Großhansdorf
ZIP/Postal Code
22927
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin I
City
Halle (Saale)
ZIP/Postal Code
06120
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Fachklinik für Lungenerkrankungen
City
Immenhausen
ZIP/Postal Code
34376
Country
Germany
Individual Site Status
Completed
Facility Name
SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein; Onk & Pal
City
Löwenstein
ZIP/Postal Code
74245
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Gemeinschaftspraxis für Hämatologie und Onkologie
City
Münster
ZIP/Postal Code
48153
Country
Germany
Individual Site Status
Completed
Facility Name
Klinik Schillerhöhe; Pneumologische Onkologie
City
Stuttgart
ZIP/Postal Code
70376
Country
Germany
Individual Site Status
Completed
Facility Name
Sotiria Hospital
City
Athens
ZIP/Postal Code
104 31
Country
Greece
Individual Site Status
Active, not recruiting
Facility Name
Metropolitan Hospital
City
Athens
ZIP/Postal Code
185 47
Country
Greece
Individual Site Status
Completed
Facility Name
Univ General Hosp Heraklion; Medical Oncology
City
Heraklion
ZIP/Postal Code
711 10
Country
Greece
Individual Site Status
Withdrawn
Facility Name
University Hospital of Larissa;Department of Medical Oncology
City
Larissa
ZIP/Postal Code
411 10
Country
Greece
Individual Site Status
Completed
Facility Name
Diavalkaniko Hospital
City
Thessaloniki
ZIP/Postal Code
570 01
Country
Greece
Individual Site Status
Active, not recruiting
Facility Name
Orszagos Koranyi TBC es Pulmonologiai Intezet
City
Budapest
ZIP/Postal Code
1121
Country
Hungary
Individual Site Status
Active, not recruiting
Facility Name
Veszprem Megyei Onkormanyzat Tudogyogyintezete; Tudogyogyaszati Ambulancia
City
Farkasgyepu
ZIP/Postal Code
8582
Country
Hungary
Individual Site Status
Withdrawn
Facility Name
Matrai Gyogyintezet
City
Matrahaza
ZIP/Postal Code
3233
Country
Hungary
Individual Site Status
Active, not recruiting
Facility Name
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
City
Szolnok
ZIP/Postal Code
5004
Country
Hungary
Individual Site Status
Terminated
Facility Name
Azienda Ospedaliera San Giuseppe Moscati
City
Avellino
State/Province
Campania
ZIP/Postal Code
83100
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
A.O. Universitaria Di Parma; Oncologia Medica
City
Parma
State/Province
Emilia-Romagna
ZIP/Postal Code
43100
Country
Italy
Individual Site Status
Withdrawn
Facility Name
Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica
City
Roma
State/Province
Lazio
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Azienda Ospedaliera San Camillo Forlanini
City
Roma
State/Province
Lazio
ZIP/Postal Code
151
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20141
Country
Italy
Individual Site Status
Completed
Facility Name
Asst Di Monza
City
Monza
State/Province
Lombardia
ZIP/Postal Code
20900
Country
Italy
Individual Site Status
Completed
Facility Name
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
City
Rozzano
State/Province
Lombardia
ZIP/Postal Code
20089
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Azienda Sanitaria Ospedaliera S Luigi Gonzaga; SSD Oncologia Polomonare (II PAD. IV PIANO)
City
Orbassano
State/Province
Piemonte
ZIP/Postal Code
10043
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
City
Sant'Andrea Delle Fratte (PG)
State/Province
Umbria
ZIP/Postal Code
06132
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
City
Padova
State/Province
Veneto
ZIP/Postal Code
35128
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Aichi Cancer Center
City
Aichi
ZIP/Postal Code
464-8681
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
National Cancer Center Hospital East
City
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Kyushu University Hospital
City
Fukuoka
ZIP/Postal Code
812-8582
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Sendai Kousei Hospital
City
Miyagi
ZIP/Postal Code
980-0873
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Niigata Cancer Center Hospital
City
Niigata
ZIP/Postal Code
951-8566
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Okayama University Hospital
City
Okayama
ZIP/Postal Code
700-8558
Country
Japan
Individual Site Status
Withdrawn
Facility Name
Osaka International Cancer Institute
City
Osaka
ZIP/Postal Code
541-8567
Country
Japan
Individual Site Status
Completed
Facility Name
Kindai University Hospital
City
Osaka
ZIP/Postal Code
589-8511
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Saitama Cancer Center
City
Saitama
ZIP/Postal Code
362-0806
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
National Hospital Organization Kinki-Chuo Chest Medical Center
City
Sakai-shi
ZIP/Postal Code
591-8555
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Shizuoka Cancer Center
City
Shizuoka
ZIP/Postal Code
411-8777
Country
Japan
Individual Site Status
Completed
Facility Name
National Cancer Center Hospital
City
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
The Cancer Institute Hospital of JFCR
City
Tokyo
ZIP/Postal Code
135-8550
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Chungbuk National University Hospital
City
Cheongju-si
ZIP/Postal Code
28644
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
National Cancer Center
City
Goyang-si
ZIP/Postal Code
10408
Country
Korea, Republic of
Individual Site Status
Withdrawn
Facility Name
Ajou University Medical Center
City
Gyeonggi-do
ZIP/Postal Code
16499
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Gachon University Gil Medical Center
City
Incheon
ZIP/Postal Code
21565
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Chonnam National University Hwasun Hospital
City
Jeollanam-do
ZIP/Postal Code
58128
Country
Korea, Republic of
Individual Site Status
Terminated
Facility Name
Seoul National University Bundang Hospital
City
Seongnam-si
ZIP/Postal Code
463-707
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Kangbuk Samsung Medical Center
City
Seoul
ZIP/Postal Code
03181
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Severance Hospital, Yonsei University Health System
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Korea University Guro Hospital
City
Seoul
ZIP/Postal Code
08308
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
St. Vincent's Hospital
City
Suwon
ZIP/Postal Code
442-723
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Health Pharma Professional Research
City
Cdmx
State/Province
Mexico CITY (federal District)
ZIP/Postal Code
03100
Country
Mexico
Individual Site Status
Active, not recruiting
Facility Name
Cryptex Investigacion Clinica SA de CV
City
Mexico
State/Province
Mexico CITY (federal District)
ZIP/Postal Code
06100
Country
Mexico
Individual Site Status
Completed
Facility Name
AVIX Investigación Clínica S.C
City
Monterrey
State/Province
Nuevo LEON
ZIP/Postal Code
64710
Country
Mexico
Individual Site Status
Terminated
Facility Name
Cuidados oncologicos
City
Querétaro
State/Province
Queretaro
ZIP/Postal Code
76000
Country
Mexico
Individual Site Status
Active, not recruiting
Facility Name
Jeroen Bosch Ziekenhuis
City
'S Hertogenbosch
ZIP/Postal Code
5223 GZ
Country
Netherlands
Individual Site Status
Completed
Facility Name
Hagaziekenhuis, locatie Leyweg
City
Den-Haag
ZIP/Postal Code
2545 AA
Country
Netherlands
Individual Site Status
Completed
Facility Name
Ziekenhuis Gelderse Vallei
City
EDE
ZIP/Postal Code
6716 RP
Country
Netherlands
Individual Site Status
Active, not recruiting
Facility Name
Medisch Centrum Leeuwarden
City
Leeuwarden
ZIP/Postal Code
8934 AD
Country
Netherlands
Individual Site Status
Active, not recruiting
Facility Name
Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica
City
Arequipa
ZIP/Postal Code
5154
Country
Peru
Individual Site Status
Completed
Facility Name
Instituto Nacional de Enfermedades Neoplasicas
City
Lima
ZIP/Postal Code
Lima 34
Country
Peru
Individual Site Status
Active, not recruiting
Facility Name
Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional
City
Lima
ZIP/Postal Code
Lima 41
Country
Peru
Individual Site Status
Active, not recruiting
Facility Name
Clinica Ricardo Palma
City
San Isidro
ZIP/Postal Code
Lima 27
Country
Peru
Individual Site Status
Completed
Facility Name
Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
City
Gda?sk
ZIP/Postal Code
80-214
Country
Poland
Individual Site Status
Active, not recruiting
Facility Name
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie; Oddzial onkologii z pododdzialem chemioterapii
City
Olsztyn
ZIP/Postal Code
10-357
Country
Poland
Individual Site Status
Completed
Facility Name
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
City
Otwock
ZIP/Postal Code
05-400
Country
Poland
Individual Site Status
Active, not recruiting
Facility Name
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
City
Poznan
ZIP/Postal Code
60-569
Country
Poland
Individual Site Status
Active, not recruiting
Facility Name
Main Military Clinical Hospital named after N.N. Burdenko
City
Moscow
State/Province
Moskovskaja Oblast
ZIP/Postal Code
105229
Country
Russian Federation
Individual Site Status
Terminated
Facility Name
MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy
City
Moscow
State/Province
Moskovskaja Oblast
ZIP/Postal Code
143422
Country
Russian Federation
Individual Site Status
Active, not recruiting
Facility Name
Institute of Oncology
City
St Petersburg
State/Province
Sankt Petersburg
ZIP/Postal Code
189646
Country
Russian Federation
Individual Site Status
Active, not recruiting
Facility Name
Leningrad Regional Clinical Hospital
City
St Petersburg
State/Province
Sankt Petersburg
ZIP/Postal Code
194291
Country
Russian Federation
Individual Site Status
Active, not recruiting
Facility Name
St. Petersburg Med Univ; n.a. I.P. Pavlov; Pulmonology Research
City
St Petersburg
State/Province
Sankt Petersburg
ZIP/Postal Code
197089
Country
Russian Federation
Individual Site Status
Active, not recruiting
Facility Name
St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
City
ST Petersburg
State/Province
Sankt Petersburg
ZIP/Postal Code
197758
Country
Russian Federation
Individual Site Status
Active, not recruiting
Facility Name
City Clinical Hospital #1
City
Novosibirsk
ZIP/Postal Code
630047
Country
Russian Federation
Individual Site Status
Completed
Facility Name
Regional Clinical Oncology Hospital
City
Yaroslavl
ZIP/Postal Code
150040
Country
Russian Federation
Individual Site Status
Completed
Facility Name
Clinical Center of Serbia
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Individual Site Status
Active, not recruiting
Facility Name
University Hospital Medical Center Bezanijska kosa
City
Belgrade
ZIP/Postal Code
11080
Country
Serbia
Individual Site Status
Active, not recruiting
Facility Name
Institute for pulmonary diseases of Vojvodina
City
Sremska Kamenica
ZIP/Postal Code
21204
Country
Serbia
Individual Site Status
Completed
Facility Name
Hospital Universitario Germans Trias i Pujol
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Universitario Puerta de Hierro - Majadahonda
City
Majadahonda
State/Province
Madrid
ZIP/Postal Code
28220
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital General Universitario de Alicante
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital 12 de Octubre; Servicio de Digestivo
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Regional Universitario de Malaga
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Universitario Virgen del Rocío
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hosp Clinico Univ Lozano Blesa; División De Oncología Médica
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Terminated
Facility Name
Universitaetsspital Basel; Onkologie
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Withdrawn
Facility Name
Inselspital Bern; Universitätsklinik für medizinische Onkologie
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Active, not recruiting
Facility Name
CHUV; Departement d'Oncologie
City
Lausanne
ZIP/Postal Code
1011
Country
Switzerland
Individual Site Status
Active, not recruiting
Facility Name
Kantonsspital St.Gallen Medizin Onkologie; Klinik fuer Onkologie und Haematologie
City
St. Gallen
ZIP/Postal Code
9000
Country
Switzerland
Individual Site Status
Active, not recruiting
Facility Name
Kaohsiung Medical University Chung-Ho Memorial Hospital
City
Kaohsiung City
ZIP/Postal Code
807
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine
City
Kaohsiung
ZIP/Postal Code
83301
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Taipei Medical University ?Shuang Ho Hospital
City
New Taipei City
ZIP/Postal Code
23561
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Taichung Veterans General Hospital; Dept of Internal Medicine
City
Taichung
ZIP/Postal Code
407
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
National Cheng Kung Uni Hospital; Dept of Hematology and Oncology
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology
City
Taipei
ZIP/Postal Code
112
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Chang Gung Memorial Hospital - Linkou Branch
City
Taipei
Country
Taiwan
Individual Site Status
Completed
Facility Name
National Taiwan University Hospital; Oncology
City
Zhongzheng Dist.
ZIP/Postal Code
10048
Country
Taiwan
Individual Site Status
Completed
Facility Name
Chulalongkorn Hospital; Medical Oncology
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Individual Site Status
Active, not recruiting
Facility Name
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
City
Bangkok
ZIP/Postal Code
10400
Country
Thailand
Individual Site Status
Completed
Facility Name
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Individual Site Status
Active, not recruiting
Facility Name
Songklanagarind Hospital; Department of Internal Medicine, Division of Respiratory
City
Songkhla
ZIP/Postal Code
90110
Country
Thailand
Individual Site Status
Active, not recruiting
Facility Name
Adana Baskent University Hospital; Medical Oncology
City
Adana
ZIP/Postal Code
01120
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
Hacettepe University Medical Faculty
City
Ankara
ZIP/Postal Code
06100
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
Istanbul University Cerrahpasa Faculty of Medicine
City
Istanbul
ZIP/Postal Code
34098
Country
Turkey
Individual Site Status
Recruiting
Facility Name
Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
City
Izmir
ZIP/Postal Code
35110
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
City
Kadiköy
ZIP/Postal Code
34722
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
Inonu University Medical Faculty of Medicine; Medical Oncology Department
City
Malatya
ZIP/Postal Code
44280
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
City Clinical Hospital #4
City
Dnipropetrovsk
ZIP/Postal Code
49102
Country
Ukraine
Individual Site Status
Active, not recruiting
Facility Name
Ivano-Frankivsk Regional Oncology Center
City
Ivano-Frankivsk
ZIP/Postal Code
76018
Country
Ukraine
Individual Site Status
Completed
Facility Name
ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council; Chemotherapy Department
City
Kryvyi Rih
ZIP/Postal Code
50048
Country
Ukraine
Individual Site Status
Active, not recruiting
Facility Name
Sumy Regional Clinical Onc Ctr
City
Sumy
ZIP/Postal Code
40005
Country
Ukraine
Individual Site Status
Withdrawn
Facility Name
Uzhgorod Nat. University Central Municip Hosp; Onc Center
City
Uzhgorod
ZIP/Postal Code
88000
Country
Ukraine
Individual Site Status
Completed

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Learn more about this trial

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

We'll reach out to this number within 24 hrs